Acquisition - HealthQuill

Swiss healthcare multinational F. Hoffmann-La Roche AG will acquire US-based 89bio Inc. for a deal worth up to $3.5 billion to expand its metabolic disease portfolio.

Roche to buy 89bio Inc for $3.5 billion to expand metabolic disease portfolio

Swiss healthcare multinational F. Hoffmann-La Roche AG will acquire US-based 89bio Inc. for a deal worth up to $3.5 billion to expand its.

by HealthQuill
September 18, 2025
0 Comments

Merck & Co. will acquire UK-based Verona Pharma Plc for about $10 billion to gain access to a respiratory drug approved by the US regulator, according to a statement from Merck.

Drugs Health Pharma

Merck to acquire Verona Pharma for $10 billion to net respiratory drug

HQ Team July 9, 2025: Merck & Co. will acquire UK-based Verona Pharma Plc for about $10 billion and gain access to a.

by HealthQuill
July 9, 2025
0 Comments

Illumina, Inc. will acquire California-based SomaLogic, a company that is involved in identifying and quantifying proteins within a cell, for $425 million, according to a company statement.

Drugs Health Pharma

Illumina to acquire proteomics company SomaLogic in $425 million all cash deal

HQ Team June 23, 2025: Illumina, Inc. will acquire California-based SomaLogic, a company that is involved in identifying and quantifying proteins within a.

by HealthQuill
June 23, 2025
0 Comments

Supernus Pharmaceuticals, Inc. will acquire Sage Therapeutics, Inc. for a total consideration of up to $795 million, to gain access to a medicine to treat postpartum depression.

Drugs Health Pharma

Supernus Pharma to acquire Sage Therapeutics for $795 million all cash

HQ Team June 22, 2025: Supernus Pharmaceuticals, Inc. will acquire Sage Therapeutics, Inc. for a total consideration of up to $795 million, as.

by HealthQuill
June 22, 2025
0 Comments

Eli Lilly and Company will acquire gene-editing startup Verve Therapeutics, Inc. for up to $1.3 billion to pocket an early-stage experimental therapy and to develop once-in-a-lifetime treatments for cardiovascular diseases.

Drugs Health Pharma

Eli Lilly to buy Verve for $1.3 billion, expands heart therapy segment

HQ Team June 19, 2025: Eli Lilly and Company will acquire gene-editing startup Verve Therapeutics, Inc. for up to $1.3 billion to pocket an.

by HealthQuill
June 19, 2025
0 Comments

Germany’s BioNTech SE will acquire CureVac N.V., which develops therapies based on messenger RNA, for $1.25 billion in an all-stock deal to expand the former’s mRNA-based cancer immunotherapy candidates.

Drugs Health Pharma

BioNTech SE to acquire CureVac for $1.25 billion in all-stock deal

HQ Team June 12, 2025: Germany’s BioNTech SE will acquire CureVac N.V., which develops therapies based on messenger RNA, for $1.25 billion in.

by HealthQuill
June 12, 2025
0 Comments

Regeneron Pharmaceuticals, Inc. plans to buy most of the assets of the bankrupt genetics and biotechnology company, 23andMe Holding, for $256 million.

Drugs Medical Pharma

Regeneron to buy bankrupt 23andMe Holding assets for $256 million

HQ Team May 20, 2025: Regeneron Pharmaceuticals, Inc. plans to buy most of the assets of the bankrupt genetics and biotechnology company, 23andMe.

by HealthQuill
May 20, 2025
0 Comments

Switzerland’s pharmaceutical company, Novartis AG, will acquire Regulus Therapeutics for about $1.7 billion to get access to a drug to treat a genetic kidney disease called autosomal dominant polycystic kidney disease.

Drugs Health Pharma

Novartis buys Regulus for $1.7b to grab genetic kidney disease drug

HQ Team April 30, 2025: Switzerland’s pharmaceutical company, Novartis AG, will acquire Regulus Therapeutics for about $1.7 billion to get access to a.